Boca Raton, Florida · June 16, 2026
5-Star Google Reviews
★★★★★
Baker Legal Team is reviewing and accepting Dupixent lawsuit claims nationwide for patients diagnosed with cutaneous T-cell lymphoma (CTCL) or another form of T-cell lymphoma after using the prescription drug Dupixent (dupilumab).
Free, confidential case review — no attorney fees or costs unless we recover compensation.
Elevated CTCL Risk
Federal MDL created June 4, 2026 — U.S. District Court for the District of New Jersey, before Judge Zahid N. Quraishi
Lawsuits at formation, drawn from 12 federal districts, with several more expected to follow
Our announcement follows a major step in the litigation — the June 4, 2026 creation of a federal multidistrict litigation that centralizes these cases before a single judge.
On June 4, 2026, the U.S. Judicial Panel on Multidistrict Litigation created MDL No. 3180, titled In re Dupixent (Dupilumab) Products Liability Litigation, and transferred the federal cases to the U.S. District Court for the District of New Jersey before Judge Zahid N. Quraishi. At its formation the litigation included 15 lawsuits from 12 federal districts, with several more cases identified as likely to follow. The claims name Regeneron Pharmaceuticals and Sanofi-Aventis U.S., the companies that make and sell Dupixent, and allege that they failed to warn patients and physicians about a possible link between the drug and T-cell lymphoma.
A multidistrict litigation is not a class action. Each person keeps a separate, individual claim and is not bound by a single group result. The cases share pretrial steps — discovery, expert testimony, and key rulings — before one judge, then rise or fall on their own facts. For patients spread across the country, that structure pools resources and puts coordinated pressure on the defendants in one courtroom. The panel currently centers the litigation on CTCL claims and left room for related T-cell lymphoma cases to be added later.
We are accepting these claims now because the timeline matters. Every claim carries a filing deadline that depends on the patient’s state and the date of diagnosis, and once it passes, the right to recover can be lost for good.
Elevated CTCL risk among treated atopic-dermatitis patients — Journal of the American Academy of Dermatology, 2024
FDA added Dupixent + CTCL to its quarterly serious-risk signal list (FAERS) — still no specific label warning
Dupixent is a widely used biologic that treats eczema, asthma, and other inflammatory conditions. Since its 2017 approval it has been prescribed to hundreds of thousands of patients in the United States. The lawsuits concern a group of those patients who developed T-cell lymphoma after treatment, most often cutaneous T-cell lymphoma and its subtypes mycosis fungoides and Sézary syndrome.
Several peer-reviewed studies have reported higher rates of CTCL among Dupixent users. A 2024 retrospective cohort study in the Journal of the American Academy of Dermatology found that patients treated for atopic dermatitis faced a risk of a CTCL diagnosis on the order of three to four times higher than untreated patients, depending on the model. A 2025 study in the European Respiratory Journal reported a similarly elevated risk among asthma patients that climbed the longer patients stayed on the drug. These studies report an association, causation has not been decided in court, and the manufacturers dispute the claims.
On March 31, 2025, the FDA added Dupixent and cutaneous T-cell lymphoma to its quarterly list of potential signals of serious risk drawn from its adverse event reporting system, and stated it was evaluating whether regulatory action is needed. As of the summer of 2026, the FDA-approved Dupixent label still does not carry a specific warning about CTCL or lymphoma. That gap — a recognized safety signal without a matching warning — is central to the failure-to-warn claims. Plaintiffs allege three overlapping theories — that the drug may trigger the cancer, accelerate a cancer already present, or mask early signs of CTCL that resemble eczema and delay diagnosis.
“When a manufacturer has information suggesting its product may be linked to cancer, patients and their doctors deserve to know. These lawsuits are about that duty to warn. We want affected patients to get clear answers and a free review of their options, without any pressure or cost.”
— Robert B. Baker, Founder, Baker Legal Team · Board-Certified Civil Trial Lawyer
We are offering a free, confidential case review to patients who used Dupixent and were later diagnosed with a T-cell lymphoma. In general, these cases involve a person who:
We handle Dupixent claims on a contingency basis, which means no attorney fees and no costs unless we recover compensation. We also encourage patients not to stop taking any prescribed medication without first consulting their physician — that is a medical decision, and a case review addresses only the legal timeline.
Patients can start a free, confidential case review, call Baker Legal Team at 888-468-4608, or learn more on our Dupixent lawsuit page. Additional plain-language information is available at ctcllawyer.com, the dedicated resource our firm built for this litigation.
Baker Legal Team is a boutique trial firm led by Robert B. Baker, one of fewer than 1% of Florida attorneys who hold Board Certification in Civil Trial Law. Over more than three decades we have recovered more than $400 million for clients across more than 50 jury trials, including a $39 million verdict in Archer and Perez v. Yamaha, the largest personal watercraft verdict in U.S. history and a result that forced every major manufacturer in that industry to redesign its product. Robert personally handles the cases the firm accepts, and our experience includes coordinating a pharmaceutical mass tort as state liaison counsel in the breast implant litigation. We take on manufacturers and insurers that put profit ahead of safety, and we take cases to trial when necessary.
Recovered for clients
Trial experience across more than 50 jury trials
Board-certified in Civil Trial Law among Florida attorneys
This announcement reflects the status of the Dupixent litigation as of July 2026. Baker Legal Team will update it as MDL No. 3180 develops.
Free & Confidential
If you used Dupixent and were later diagnosed with CTCL, mycosis fungoides, Sézary syndrome, or another T-cell lymphoma, get a free review of your options — no pressure and no cost. No attorney fees or costs unless we recover compensation for you.
Takes about 60 seconds. No obligation.
Failed Cartiva toe implant — or diagnosed with T-cell lymphoma after taking Dupixent? You may be entitled to compensation. No fees unless we win.
